These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9494064)

  • 1. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
    Kromer W; Krüger U; Huber R; Hartmann M; Steinijans VW
    Pharmacology; 1998 Feb; 56(2):57-70. PubMed ID: 9494064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
    Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
    Kromer W
    Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
    Nishioka K; Nagao T; Urushidani T
    Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
    Beil W; Staar U; Sewing KF
    Eur J Pharmacol; 1992 Aug; 218(2-3):265-71. PubMed ID: 1330598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics--a relevant factor for the choice of a drug?
    Benet LZ; Zech K
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():25-32. PubMed ID: 8180291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
    Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
    Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of pantoprazole in man.
    Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S7-16. PubMed ID: 8793599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of pantoprazole in man.
    Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
    Int J Clin Pharmacol Ther; 1996 May; 34(5):185-94. PubMed ID: 8738854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals.
    Ryan CA; Sanchez LC; Giguère S; Vickroy T
    Equine Vet J; 2005 Jul; 37(4):336-41. PubMed ID: 16028623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
    Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
    J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
    Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
    Leitner A; Zöllner P
    Wien Med Wochenschr; 2002; 152(21-22):568-73. PubMed ID: 12506681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
    Bliesath H; Huber R; Hartmann M; Lühmann R; Wurst W
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S18-24. PubMed ID: 8793600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.